Joint Laboratory of Large-scale Intelligence Model of Neuromedicine

The Joint Laboratory of Large-scale Intelligence Model of Neuromedicine is established by the Guangdong Institute of Intelligent Science and Technology and Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. Based on brain-like science and AI large model technology, the joint laboratory aims to construct a new generation of neuromedical large models with embodied cognitive abilities. It explores the mechanisms of human embodied cognition, studies the diagnosis, intervention, and enhancement of cognitive health, and seeks to understand and reveal the ultimate propositions between complex individual cognition and life evolution. The main research directions of the laboratory include the acquisition and integration of multi-source multimodal big data, the development of low-power high-efficiency large model architectures for brain-like computing, the research of neuromedical large model systems, and the construction of comprehensive assessment models for embodied cognition. By integrating data from fields such as neuroimaging, genomics, behavioral science, and physiological monitoring, the laboratory is committed to promoting a paradigm shift in cognitive neuromedicine research. It aims to provide comprehensive cognitive health assessments and personalized intervention strategies through mind-body integrated evaluations. By deeply analyzing multidimensional data through large models, the laboratory provides comprehensive portraits of individual mental and physical states, early identification of cognitive health issues, aids in optimizing cognitive structures and improving efficiency, promotes the overall development of cognitive science, and brings revolutionary breakthroughs to related fields.

Joint Directors

Joint Director Prof. Xu Zhang, Neuroscientist, Academician of Chinese Academy of Sciences, TWAS (The World Academy of Sciences for the advancement of science in developing countries) Fellow, and Member of Chinese Academy of Medical Sciences. He received his Ph.D. of Neuroscience from Karolinska Institute, Sweden in July, 1994. In 1994, he successively worked as a lecturer, associate professor and professor, and deputy director at the Neuroscience Institute of Fourth Military Medical University. In 1999, he became a professor and principal investigator in Lab of Sensory System at Institute of Neuroscience, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. In 2021, he was appointed as a professor of Shanghai Institute for Advanced Study, Chinese Academy of Sciences, Director of Shanghai Brain-Intelligence Engineering Center, and President of Guangdong Institute of Intelligent Science and Technology, respectively. He is also the President of the Chinese Neuroscience Society, the Vice President of the Chinese Society of Cell Biology, and the Vice President of the Pain Branch of the Chinese Medical Association.

Dr. Jinhe Li is currently the CEO of Green Valley Pharmaceutical Technology Co., Ltd. He has been engaged in Alzheimer's disease (AD) research and drug development for many years. His achievements include the discovery of the AD gene PS2, initiating the AbbVie-Google AI collaboration plan, and promoting international cooperative research and clinical trials of AD/GV-971 (sodium oligomannate). Dr. Li holds a Ph.D. in Biochemistry and Molecular Biology from the State University of New York and completed his postdoctoral training in Neurobiology at Harvard Medical School. He is a permanent grant reviewer for the National Institutes of Health (NIH) and a Lefler Scholar at Harvard Medical School.

Introduction to Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd.

Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. upholds the mission of "improving human cognitive health" and focuses on the innovation of diagnostic and therapeutic products for neurodegenerative diseases. After years of effort, on November 2, 2019, the company successfully developed GV-971 (sodium oligomannate, also known as 九期一®), the world's first oligosaccharide drug targeting the brain-gut axis for the treatment of Alzheimer's disease, breaking the 17-year drought in new drug innovation in this field. Building on the foundation of GV-971, Green Valley continually promotes theoretical innovation in the brain-gut axis, constructing an integrated clinical-information-research-market platform. This platform has created a collaborative cognitive industry ecosystem involving experts, clinicians, and patients, opening a new realm in cognitive life science research. The company aims to improve human cognitive health by offering innovative drugs and diagnostic solutions, driven by artificial intelligence and brain-gut axis theory. Through the integration of global resources, Green Valley achieves its mission.

Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. 

website and WeChat official account: Website: https://www.greenvalleypharma.com/

WeChat official account: 绿谷医药科技.